| Name | Title | Contact Details |
|---|
Islet Sciences is a clinical stage biotechnology company engaged in the research, development, and commercialization of new medicines and technologies for the treatment and diagnosis of metabolic disease and related indications where there is significant measurable unmet medical need. The rising incidence of obesity is associated with many obesity-related health complications, including cardiovascular disease, diabetes, hyperlipidemia, hypertension, nonalcoholic fatty liver disease/steatohepatitis (NAFLD/NASH). This constellation is also recognized as the metabolic syndrome and is characterized by underlying insulin resistance. These various diseases have interrelated risk factors and markers, such that often treatment of one disease may allow new therapies and opportunities for treatment in one of these related indications. Our focused effort to develop new therapies and related diagnostics for metabolic related diseases establishes us as a recognized leader in a large and growing market.
Pearl Therapeutics is a Redwood City, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
OriGene Technologies is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
HealthLoop automates patient engagement to help health providers reduce cost, improve outcomes and deliver a 5-star patient experience. Reassuring guidance each step of the way connects care teams with patients who need it most. HealthLoop enables value-based care for hospitals to monitor at-risk populations, provide outreach when most needed and track patients through an episode of care. Patients rate their doctors with a 5-star experience and providers realize better efficiencies with an automated patient check-in approach. Located in Mountain View, HealthLoop facilitates over 25,000 automated check-ins each month.
Ironwood is committed to the art and science of making medicines. Patient needs shape our business. They inform our drugmaking process. We rely on patients to help us understand and address those unmet needs. Whether we’re transforming knowledge into medicine or tackling the equally challenging task of delivering that medicine to people around the world, patients inspire us. Shareholders shape our success. Being a shareholder of Ironwood is about more than owning our shares, it's about being an owner of our business. We hope to generate outstanding returns for our shareholders, inspiring their continued support so that we can create more medicines and build an enduring pharmaceutical company. Employees shape our future. At Ironwood, we’re building a team of talented individuals who embrace the incredibly challenging task of making medicines. All our employees are equity holders, which means we are careful stewards of our resources, and we share the responsibility to build and grow this company. Our discovery and development processes have generated a product that’s approved in the United States, the European Union and a number of other countries, as well as a robust pipeline. We hope to continue earning the right to make medicines and, one step at a time, build an enduring pharmaceutical company that helps patients lead better lives.